Abstract
In a far-reaching decision about scientific evidence in federal cases handed down at the very end of the 1992-1993 term, the U.S. Supreme Court implicated medical practice guidelines in indirect, profound, yet highly uncertain ways. In Daubert v Merrell Dow Pharmaceuticals, Inc the Court ruled that judges must actively screen novel scientific evidence to assure both its relevance and its reliability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Joint Commission Journal on Quality Improvement
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
